- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04615936
Nasal Photodisinfection COVID-19 Proof of Concept Study
October 29, 2021 updated by: Sunnybrook Health Sciences Centre
Methylene Blue-mediated Photodisinfection for SARS-CoV-2 in the Upper Respiratory Tract
The study proposes to test photodisinfection (PDF) on SARS-CoV-2 in the nose.
The study will use Health Canada approved Steriwave™ Nasal Decolonization (ND) in he nostril of patients infected with SARS-CoV-2.
Participants are swabbed for SARS-CoV-2 before and after the PDF treatment.
For the study, a small group of healthcare workers who have tested positive for SARS-CoV-2 will be included.
They will not undergo the treatment but will need to swab their noses multiple times over the next 5 days.
This nil group will provide the effect (if any) of swabbing SARS-CoV-2 levels in the nose.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
The study proposes to test photodisinfetion (PDF) on levels of SARS-CoV-2 in the nose.
The study will use Health Canada approved Steriwave™ Nasal Decolonization (ND) in patients infected with SARS-CoV-2 .
Currrently, PDF is being used at some institutions before surgery to lower the risk of postoperative infection.
PDF uses a Methylene Blue (MB) nasal spray, followed by 5 minutes of red-light exposure through a small light-diffusing applicator.
This will need to be placed into each nostril.
Participants are swabbed for SARS-CoV-2 before and after treatment.
In addition to the patients testing positive for SARS-CoV-2, there will also be a small group of healthcare workers who have tested positive that will be included.
Though they are not undergoing treatment, they will swab their own noses multiple times over a period of 5 days.
This will allow us to evaluate the effect (if any) of swabbing on SARS-CoV-2 levels in the nose.
The study hypothesis is that MB-mediated PDF will show the ability to kill SARS-CoV-2 which will consequently confirm its efficacy as a first line defense against the virus.
Study Type
Interventional
Enrollment (Actual)
45
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Ontario
-
Toronto, Ontario, Canada, M4N 3M5
- Sunnybrook Health Sciences Centre
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria (patient population):
- Recent SARS-CoV-2+ diagnosis
- Present in hospital
Inclusion Criteria (healthcare workers):
- Recent SARS-CoV-2+ diagnosis
- Ability to self-administer nasal swabs
Exclusion Criteria (patient population):
- Immediate requirement for intubation (i.e. emergency airway) or inability to maintain independent oral airway
Exclusion Criteria (healthcare workers):
- None
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Methylene Blue-Photodisinfection
The Health-Canada approved Steriwave system (Ondine Biomedical, BC) will be used to deliver the Methylene Blue-Photodisinfection (MB-PDF) to the anterior nares.
|
Participants will receive a pre-treatment nasal swab followed MB-PDF, this involves an MB nasal spray, followed by five minutes of red-light exposure into each nostril.
Ten minutes after the treatment, a post treatment nasal swab will be performed.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
RT-qPCR
Time Frame: 30 minutes
|
The main endpoint is microbiological; RT-qPCR will be conducted on the pre and post treatment swabs and the change in cycle threshold value will be measured
|
30 minutes
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: Cari Whyne, PhD, Sunnybrook Research Institute
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
October 13, 2020
Primary Completion (Actual)
July 7, 2021
Study Completion (Actual)
October 19, 2021
Study Registration Dates
First Submitted
November 2, 2020
First Submitted That Met QC Criteria
November 2, 2020
First Posted (Actual)
November 4, 2020
Study Record Updates
Last Update Posted (Actual)
November 8, 2021
Last Update Submitted That Met QC Criteria
October 29, 2021
Last Verified
October 1, 2021
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Coronaviridae Infections
- Nidovirales Infections
- RNA Virus Infections
- Virus Diseases
- Infections
- Respiratory Tract Infections
- Respiratory Tract Diseases
- Pneumonia, Viral
- Pneumonia
- Lung Diseases
- COVID-19
- Coronavirus Infections
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Methylene Blue
Other Study ID Numbers
- NasalPDF001
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on COVID-19
-
University of Roma La SapienzaQueen Mary University of London; Università degli studi di Roma Foro Italico; Bios Prevention SrlCompletedPost Acute Sequelae of COVID-19 | Post COVID-19 Condition | Long-COVID | Chronic COVID-19 SyndromeItaly
-
Yang I. PachankisActive, not recruitingCOVID-19 Respiratory Infection | COVID-19 Stress Syndrome | COVID-19 Vaccine Adverse Reaction | COVID-19-Associated Thromboembolism | COVID-19 Post-Intensive Care Syndrome | COVID-19-Associated StrokeChina
-
Massachusetts General HospitalRecruitingPost Acute COVID-19 Syndrome | Long COVID | Post Acute Sequelae of COVID-19 | Long COVID-19United States
-
Indonesia UniversityRecruitingPost-COVID-19 Syndrome | Long COVID | Post COVID-19 Condition | Post-COVID Syndrome | Long COVID-19Indonesia
-
Erasmus Medical CenterDa Vinci Clinic; HGC RijswijkNot yet recruitingPost-COVID-19 Syndrome | Long COVID | Long Covid19 | Post COVID-19 Condition | Post-COVID Syndrome | Post COVID-19 Condition, Unspecified | Post-COVID ConditionNetherlands
-
Dr. Soetomo General HospitalIndonesia-MoH; Universitas Airlangga; Biotis Pharmaceuticals, IndonesiaRecruitingCOVID-19 Pandemic | COVID-19 Vaccines | COVID-19 Virus DiseaseIndonesia
-
University of Witten/HerdeckeInstitut für Rehabilitationsforschung NorderneyCompletedPost-COVID-19 Syndrome | Long-COVID-19 SyndromeGermany
-
Jonathann Kuo, MDActive, not recruitingSARS-CoV2 Infection | Post-COVID-19 Syndrome | Dysautonomia | Post Acute COVID-19 Syndrome | Long COVID | Long Covid19 | COVID-19 Recurrent | Post-Acute COVID-19 | Post-Acute COVID-19 Infection | Post Acute Sequelae of COVID-19 | Dysautonomia Like Disorder | Dysautonomia Orthostatic Hypotension Syndrome | Post... and other conditionsUnited States
-
University Hospital, Ioannina1st Division of Internal Medicine, University Hospital of IoanninaRecruitingCOVID-19 Pneumonia | COVID-19 Respiratory Infection | COVID-19 Pandemic | COVID-19 Acute Respiratory Distress Syndrome | COVID-19-Associated Pneumonia | COVID 19 Associated Coagulopathy | COVID-19 (Coronavirus Disease 2019) | COVID-19-Associated ThromboembolismGreece
Clinical Trials on Methylene-Blue Photodisinfection
-
Pourmatroud, Elham, M.D.CompletedLaparoscopy | Tubal Patency | Methylene BlueIran, Islamic Republic of
-
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityUnknownSentinel Lymph Node | Breast Cancer Female | Early-Stage Breast CancerChina
-
Cosmo Technologies LtdCompletedColorectal CancerUnited States, Belgium, Canada, Germany, Italy, Lithuania, Netherlands, United Kingdom
-
Seoul National University HospitalUnknown
-
University of Nove de JulhoEnrolling by invitation
-
Ondine Biomedical Inc.CompletedNosocomial Infection | Surgical Site Infections | Healthcare Associated InfectionsUnited States
-
University College, LondonUniversity College London HospitalsRecruitingFluorescence Guided SurgeryUnited Kingdom
-
University of OxfordOxford University Hospitals NHS TrustUnknown
-
Medtronic - MITGCompletedRespiratory AspirationUnited States
-
National Cancer Institute, EgyptRecruiting